Mizagliflozin (Synonyms: DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base) |
Catalog No.GC60249 |
La mizagliflozine (base libre DSP-3235) est un puissant inhibiteur du SGLT1 actif par voie orale et sélectif, avec un Ki de 27 nM pour le SGLT1 humain.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 666843-10-3
Sample solution is provided at 25 µL, 10mM.
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic drug that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation[1].
Mizagliflozin (DSP-3235 free base) (3-30 mg/kg; oral) exerts a laxative effect[1].Mizagliflozin administrated intravenously (0.3 mg/kg) and orally (3 mg/kg) declined with a short half-life (0.23 and 1.14 h, respectively)[2] Animal Model: Male Wistar rats (rat model of low-fiber-diet-induced constipation)[1]
[1]. Inoue T, et al. Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation. Eur J Pharmacol. 2017 Jul 5;806:25-31. [2]. Ohno H, et al. Absorption, disposition, metabolism and excretion of [14C]mizagliflozin, a novel selective SGLT1 inhibitor, in rats. Xenobiotica. 2019 Apr;49(4):463-473.
Average Rating: 5
(Based on Reviews and 10 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *